Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Lars IversenCurdin ConradLiv EidsmoAntonio CostanzoJoanna NarbuttAndreas PinterKülli KingoRaquel Rivera-DíazFrank KolbingerManikPrabhu NannaJennifer Annika FruehPiotr JagielloPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Secukinumab was superior to nb-UVB in treating patients with new-onset moderate to severe plaque psoriasis. The high and sustained skin clearance observed indicates that biologic treatment for psoriasis may be more effective if used early in the disease course.
Keyphrases
- end stage renal disease
- ankylosing spondylitis
- coronary artery disease
- ejection fraction
- rheumatoid arthritis
- high intensity
- newly diagnosed
- early onset
- prognostic factors
- peritoneal dialysis
- atopic dermatitis
- clinical trial
- systemic lupus erythematosus
- patient reported outcomes
- drug induced
- disease activity
- double blind
- placebo controlled